Wallace Lovell Akerley III MD
Hematologic Oncology, Thoracic Cancer
Professor of Medicine, University Utah
Join to view full profile
1950 Circle of HopeClinic 1aSalt Lake City, UT 84112
Phone+1 801-585-0100
Fax+1 801-585-7902
Dr. Akerley is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1985 - 1989
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1984 - 1985- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1981 - 1984
The Warren Alpert Medical School of Brown UniversityClass of 1981
Certifications & Licensure
CA State Medical License 1982 - Present
UT State Medical License 2002 - 2028
RI State Medical License 1989 - 2000
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
Clinical Trials
- S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Jan 01
- Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer Start of enrollment: 2007 Aug 01
- A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2004 Jun 01
Publications & Presentations
PubMed
- TTF-1-Negative Lung Adenocarcinoma: An Aggressive Subtype Refractory to Immunotherapy and KRASInhibition.Henry U Arnold, Wallace Akerley, Eric L Snyder
Journal of Thoracic Oncology. 2026-07-01 - Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, Anne C Chiang, Ji-Youn Han
Nature Medicine. 2026-06-29 - SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.Lauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, Anne C Chiang, Ji-Youn Han
Nature Medicine. 2026-06-01
Press Mentions
'I'd Been so Healthy': Radon Gas Continues to Causes Illnesses in Utah HomesOctober 27th, 2024- Do Low-Grade irAEs with Atezolizumab Predict Survival in Stage IV NSCLC?March 9th, 2023
- Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNovember 10th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
